Re: Transition and Separation Agreement and General Release of ClaimsPersonal and Confidential • March 14th, 2023 • Pardes Biosciences, Inc. • Pharmaceutical preparations • California
This letter (this “Agreement”) confirms Pardes Biosciences, Inc. (the “Company”) receipt of your notice of resignation from the Company as of the date set forth above effective as of November 30, 2022 (the “Separation Date”). During the period between the date of this Agreement and the Separation Date (the “Transition Period”), you will continue as an employee of the Company serving in the role of Chief Business and Strategy Officer with no change in your base salary. The Company thanks you for your contributions to the Company and continued assistance during this Transition Period.
